• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎:诊断、治疗和预防的综述。

COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis.

机构信息

Infectivology and Clinical Trials Research Department, Children's Hospital Bambino Gesù, 00146 Rome, Italy.

出版信息

Int J Mol Sci. 2020 Jul 21;21(14):5145. doi: 10.3390/ijms21145145.

DOI:10.3390/ijms21145145
PMID:32708112
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7404132/
Abstract

Coronavirus 2 (CoV) Severe Acute Respiratory Syndrome (SARS-CoV2) is causing a highly infectious pandemic pneumonia. Coronaviruses are positive sense single-stranded RNA viruses that infect several animal species, causing symptoms that range from those similar to the common cold to severe respiratory syndrome. The Angiotensin Converting Enzyme 2 (ACE2) is the SARS-CoV2 functional receptor. Measures are currently undertaken worldwide to control the infection to avoid disruption of the social and economic equilibrium, especially in countries with poor healthcare resources. In a guarded optimistic view, we hope that the undertaken preventive and treatment measures will at least contribute to contain viral diffusion, attenuate activity, or even eliminate SARS-CoV2. In this review, we discuss emerging perspectives for prevention/treatment of COVID-19 infection. In addition to vaccines under development, passive immunization is an open opportunity since patients develop neutralizing antibodies. A full spectrum of potential drugs for COVID-19 infections could in turn affect virus binding or enzymatic activities involved in viral replication and transcription. Furthermore, clinical trials are currently evaluating the safety and efficacy of anti-inflammatory drugs, such as tocilizumab. Bioinformatics may allow characterization of specific CD8+ and CD4+ T cell responses; thus, CoV2 T cells' frequency can be correlated with the disease severity and outcome. Combinatorial antibody phage display may be empowered to identify the immune repertoire of CoV2-specific neutralizing antibodies.

摘要

冠状病毒 2(CoV)严重急性呼吸系统综合征(SARS-CoV2)正在引发高度传染性的大流行肺炎。冠状病毒是感染多种动物物种的正链单链 RNA 病毒,引起的症状从类似于普通感冒到严重呼吸系统综合征不等。血管紧张素转换酶 2(ACE2)是 SARS-CoV2 的功能性受体。目前全球正在采取措施控制感染,以避免社会和经济平衡受到干扰,特别是在医疗资源匮乏的国家。从谨慎乐观的角度来看,我们希望所采取的预防和治疗措施至少有助于遏制病毒扩散、减轻其活性,甚至消灭 SARS-CoV2。在这篇综述中,我们讨论了 COVID-19 感染的预防/治疗的新观点。除了正在开发的疫苗外,被动免疫也是一个开放的机会,因为患者会产生中和抗体。一系列针对 COVID-19 感染的潜在药物可能会影响病毒结合或参与病毒复制和转录的酶活性。此外,临床试验目前正在评估抗炎药物(如托珠单抗)的安全性和疗效。生物信息学可能允许对特定的 CD8+和 CD4+T 细胞反应进行特征描述;因此,CoV2 T 细胞的频率可以与疾病的严重程度和结果相关联。组合抗体噬菌体展示技术可能有助于识别 CoV2 特异性中和抗体的免疫库。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef33/7404132/7e26bdfa7646/ijms-21-05145-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef33/7404132/7e26bdfa7646/ijms-21-05145-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef33/7404132/7e26bdfa7646/ijms-21-05145-g001.jpg

相似文献

1
COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis.新型冠状病毒肺炎:诊断、治疗和预防的综述。
Int J Mol Sci. 2020 Jul 21;21(14):5145. doi: 10.3390/ijms21145145.
2
Potently neutralizing and protective human antibodies against SARS-CoV-2.强效中和和保护 SARS-CoV-2 的人源抗体。
Nature. 2020 Aug;584(7821):443-449. doi: 10.1038/s41586-020-2548-6. Epub 2020 Jul 15.
3
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.2020 年大流行:当前 SARS-CoV-2 疫苗的开发。
Front Immunol. 2020 Aug 19;11:1880. doi: 10.3389/fimmu.2020.01880. eCollection 2020.
4
A human monoclonal antibody blocking SARS-CoV-2 infection.一种人源单克隆抗体阻断 SARS-CoV-2 感染。
Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y.
5
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.一种强效中和抗体可保护小鼠免受 SARS-CoV-2 感染。
J Immunol. 2020 Aug 15;205(4):915-922. doi: 10.4049/jimmunol.2000583. Epub 2020 Jun 26.
6
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.人类单克隆 SARS-CoV 抗体对 SARS-CoV-2 的交叉中和作用。
Nature. 2020 Jul;583(7815):290-295. doi: 10.1038/s41586-020-2349-y. Epub 2020 May 18.
7
A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.在小鼠中建立的 SARS-CoV-2 感染模型证明了中和抗体的保护作用。
Cell. 2020 Aug 6;182(3):744-753.e4. doi: 10.1016/j.cell.2020.06.011. Epub 2020 Jun 10.
8
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.在小动物模型中分离出有效的 SARS-CoV-2 中和抗体并预防疾病。
Science. 2020 Aug 21;369(6506):956-963. doi: 10.1126/science.abc7520. Epub 2020 Jun 15.
9
SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.SARS-CoV-2 大流行和研究空白:了解 SARS-CoV-2 与 ACE2 受体的相互作用及其对治疗的影响。
Theranostics. 2020 Jun 12;10(16):7448-7464. doi: 10.7150/thno.48076. eCollection 2020.
10
The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.SARS-CoV-2 刺突糖蛋白作为药物和疫苗靶点:与 ACE2 和抗体复合物的结构见解。
Cells. 2020 Oct 22;9(11):2343. doi: 10.3390/cells9112343.

引用本文的文献

1
Anxiety Levels among Healthcare Workers during the COVID-19 Pandemic and Attitudes towards COVID-19 Vaccines.新冠疫情期间医护人员的焦虑水平及对新冠疫苗的态度
Vaccines (Basel). 2024 Mar 28;12(4):366. doi: 10.3390/vaccines12040366.
2
Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies.重要性、应用和测定 SARS-CoV-2 中和抗体的方法的特点。
Int J Mol Sci. 2023 Mar 10;24(6):5352. doi: 10.3390/ijms24065352.
3
Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.

本文引用的文献

1
Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection.人诱导多能干细胞衍生的心肌细胞易受新冠病毒感染。
Cell Rep Med. 2020 Jul 21;1(4):100052. doi: 10.1016/j.xcrm.2020.100052. Epub 2020 Jun 29.
2
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.ChAdOx1 nCoV-19 疫苗可预防恒河猴的 SARS-CoV-2 肺炎。
Nature. 2020 Oct;586(7830):578-582. doi: 10.1038/s41586-020-2608-y. Epub 2020 Jul 30.
3
The Global Phosphorylation Landscape of SARS-CoV-2 Infection.新冠病毒感染的全球磷酸化组景观。
肺部药物递送:抗击 COVID-19 的有效且便捷的给药途径。
Drug Deliv Transl Res. 2023 Mar;13(3):705-715. doi: 10.1007/s13346-022-01251-1. Epub 2022 Oct 19.
4
The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs.MEK1/2抑制剂ATR-002(扎普诺美替尼)可协同增强直接作用抗SARS-CoV-2药物的抗病毒效果。
Pharmaceutics. 2022 Aug 25;14(9):1776. doi: 10.3390/pharmaceutics14091776.
5
Case report: SARS-CoV-2 infection as a trigger for diabetic ketoacidosis and newly detected pancreatic autoantibodies.病例报告:严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染引发糖尿病酮症酸中毒及新检测出的胰腺自身抗体
Front Endocrinol (Lausanne). 2022 Aug 10;13:983206. doi: 10.3389/fendo.2022.983206. eCollection 2022.
6
N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19) .N-氯代牛磺酸对包括 SARS-CoV-2(COVID-19)在内的呼吸道病毒具有高度活性。
Emerg Microbes Infect. 2022 Dec;11(1):1293-1307. doi: 10.1080/22221751.2022.2065932.
7
SARS-CoV-2 infection as possible downstream disease precipitator in autoantibody-positive insulin-dependent diabetes mellitus: a case report.SARS-CoV-2 感染可能是自身抗体阳性的胰岛素依赖型糖尿病下游疾病的诱发因素:一例报告。
Ital J Pediatr. 2022 Feb 23;48(1):33. doi: 10.1186/s13052-022-01226-5.
8
Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2-A Candidate for Passive Immunization against COVID-19.鸡卵黄抗体(IgY)抗严重急性呼吸综合征冠状病毒2(SARS-CoV-2)受体结合域(RBD)刺突蛋白用于COVID-19被动免疫的临床前评估。
Vaccines (Basel). 2022 Jan 17;10(1):128. doi: 10.3390/vaccines10010128.
9
Are We Paving the Way to Dig Out of the "Pandemic Hole"? A Narrative Review on SARS-CoV-2 Vaccination: From Animal Models to Human Immunization.我们是否正在为走出“疫情困境”铺平道路?SARS-CoV-2 疫苗接种的叙述性综述:从动物模型到人免疫。
Med Sci (Basel). 2021 Jul 30;9(3):53. doi: 10.3390/medsci9030053.
10
Fusion of intelligent learning for COVID-19: A state-of-the-art review and analysis on real medical data.COVID-19智能学习融合:基于真实医学数据的最新综述与分析
Neurocomputing (Amst). 2021 Oct 7;457:40-66. doi: 10.1016/j.neucom.2021.06.024. Epub 2021 Jun 16.
Cell. 2020 Aug 6;182(3):685-712.e19. doi: 10.1016/j.cell.2020.06.034. Epub 2020 Jun 28.
4
Interferon-α2b Treatment for COVID-19.干扰素-α2b 治疗 COVID-19。
Front Immunol. 2020 May 15;11:1061. doi: 10.3389/fimmu.2020.01061. eCollection 2020.
5
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.皮下注射干扰素 β-1a 治疗 COVID-19:一项非对照前瞻性试验。
Int Immunopharmacol. 2020 Aug;85:106688. doi: 10.1016/j.intimp.2020.106688. Epub 2020 Jun 7.
6
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.评估人抗 SARS-CoV-2 恢复期血浆在 COVID-19 重症成人中的疗效和安全性:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 8;21(1):499. doi: 10.1186/s13063-020-04422-y.
7
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.恢复期血浆疗法对重症和危及生命的 COVID-19 患者临床改善时间的影响:一项随机临床试验。
JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044.
8
Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma.治疗新型冠状病毒肺炎(COVID-19)患者的恢复期血浆。
Am J Pathol. 2020 Aug;190(8):1680-1690. doi: 10.1016/j.ajpath.2020.05.014. Epub 2020 May 27.
9
Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol.从新冠肺炎康复供者中提取的血浆用于治疗 COVID-19 危重症患者的研究(COVID-19 血浆研究):一项多中心研究方案。
Intern Emerg Med. 2020 Aug;15(5):819-824. doi: 10.1007/s11739-020-02384-2. Epub 2020 May 28.
10
The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.2019 年冠状病毒病疫苗在英国和世界其他地区的早期开发情况。
Immunology. 2020 Jul;160(3):223-232. doi: 10.1111/imm.13222.